Skip to main content

Table 1 Demographic and baseline characteristics of the patients

From: Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Patient Characteristics ALL patients
(Number (percent))
Total no. of patients 30 (100)
Median age, years (range) 55 (26–74)
Sex
 Female 8 (27)
 Male 22 (73)
Metastatic stage (n)
 M0 1 (3)
 M1a 6 (20)
 M1b 6 (20)
 M1c 17 (57)
Lactate dehydrogenase
  ≤ ULNa 20 (67)
  > ULN 10 (33)
ECOG
 0 19 (63)
 1 11 (37)
Primary site
 Cutaneous 24 (80)
 Mucosal 2 (7)
 Ocular 3 (10)
 Unknown primary 1 (3)
BRAF status
BRAF mutated (V600E) 9 (30)
BRAF wild type 21 (70)
Prior therapies**
 Prior adjuvant therapy 5 (17)
 Prior therapy with a BRAF inhibitor 6 (20)
Brain metastases
 Patients without brain metastases 26 (87)
 Patients with brain metastases 4 (13)
  1. aULN denotes upper limit of the normal, ** One patient (3%) received 2 weeks a of Temozolomide